JP2023535204A - コロナウイルス感染症の治療におけるカンナビジオールの応用 - Google Patents

コロナウイルス感染症の治療におけるカンナビジオールの応用 Download PDF

Info

Publication number
JP2023535204A
JP2023535204A JP2023504633A JP2023504633A JP2023535204A JP 2023535204 A JP2023535204 A JP 2023535204A JP 2023504633 A JP2023504633 A JP 2023504633A JP 2023504633 A JP2023504633 A JP 2023504633A JP 2023535204 A JP2023535204 A JP 2023535204A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
infection
pharmaceutically acceptable
formula
coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535204A5 (https=
Inventor
ウー チョン
ヨン チン
マンリー ワン
ルイユアン ツァオ
シーヨン ファン
チーホン フー
ソン リー
Original Assignee
アカデミー オブ ミリタリー メディカル サイエンシズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アカデミー オブ ミリタリー メディカル サイエンシズ filed Critical アカデミー オブ ミリタリー メディカル サイエンシズ
Publication of JP2023535204A publication Critical patent/JP2023535204A/ja
Publication of JP2023535204A5 publication Critical patent/JP2023535204A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023504633A 2020-07-24 2021-07-19 コロナウイルス感染症の治療におけるカンナビジオールの応用 Pending JP2023535204A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010722697.9 2020-07-24
CN202010722697.9A CN111686095A (zh) 2020-07-24 2020-07-24 大麻二酚在制备治疗冠状病毒感染的药物中的用途
PCT/CN2021/107001 WO2022017304A1 (zh) 2020-07-24 2021-07-19 大麻二酚在治疗冠状病毒感染中的应用

Publications (2)

Publication Number Publication Date
JP2023535204A true JP2023535204A (ja) 2023-08-16
JP2023535204A5 JP2023535204A5 (https=) 2024-07-26

Family

ID=72486807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504633A Pending JP2023535204A (ja) 2020-07-24 2021-07-19 コロナウイルス感染症の治療におけるカンナビジオールの応用

Country Status (5)

Country Link
US (1) US20230263811A1 (https=)
EP (1) EP4186496B1 (https=)
JP (1) JP2023535204A (https=)
CN (2) CN120789031A (https=)
WO (1) WO2022017304A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4126913A4 (en) * 2020-03-29 2024-09-18 Akseera Pharma Corp. INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS OF HOST CELLS AND FORMULATIONS FOR THE TREATMENT OF COVID-19
CA3179022A1 (en) * 2020-07-18 2021-10-07 Akseera Pharma Corp. Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途
KR102504114B1 (ko) 2020-09-29 2023-02-28 영남대학교 산학협력단 칸나비노이드를 유효성분으로 함유하는 중증 급성 호흡기 증후군 코로나 바이러스 2에 대한 항바이러스 조성물
CN115181791A (zh) * 2020-12-02 2022-10-14 飞象生物科技有限公司 一种筛选和识别具有抗病毒属性的小分子的方法
CN115177602A (zh) * 2021-04-06 2022-10-14 中国科学院微生物研究所 一种治疗结核病的药物
CN114732804A (zh) * 2022-03-15 2022-07-12 亨玛(浙江)生物科技有限公司 一种含大麻二酚cbd提取物在新型冠状病毒肺炎的应用
CN115778941A (zh) * 2022-11-18 2023-03-14 哈尔滨医科大学 一种抗新冠病毒联合用药物组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081634A2 (en) * 2018-10-16 2020-04-23 George Mason Research Foundation, Inc. Compositions and methods for modulation of extracellular vesicle release and treatment of neurological disorders
JP2023524876A (ja) * 2020-05-11 2023-06-13 アド アドヴァンスト ドラッグ デリヴァリー テクノロジーズ リミテッド カンナビノイドの使用および製剤
JP2023534361A (ja) * 2020-05-11 2023-08-09 アド アドヴァンスト ドラッグ デリヴァリー テクノロジーズ リミテッド カンナビノイドの使用および製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012498A2 (en) * 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
CN102924446B (zh) * 2011-08-11 2015-08-26 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
EP4126913A4 (en) * 2020-03-29 2024-09-18 Akseera Pharma Corp. INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS OF HOST CELLS AND FORMULATIONS FOR THE TREATMENT OF COVID-19
CN120789031A (zh) * 2020-07-24 2025-10-17 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081634A2 (en) * 2018-10-16 2020-04-23 George Mason Research Foundation, Inc. Compositions and methods for modulation of extracellular vesicle release and treatment of neurological disorders
JP2023524876A (ja) * 2020-05-11 2023-06-13 アド アドヴァンスト ドラッグ デリヴァリー テクノロジーズ リミテッド カンナビノイドの使用および製剤
JP2023534361A (ja) * 2020-05-11 2023-08-09 アド アドヴァンスト ドラッグ デリヴァリー テクノロジーズ リミテッド カンナビノイドの使用および製剤

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"NCT04467918", [ONLINE], JPN6025024395, 14 July 2020 (2020-07-14), ISSN: 0005753825 *
BO WANG; ET AL: "IN SEARCH OF PREVENTATIVE STRATEGIES: NOVEL ANTI-INFLAMMATORY HIGH-CBD CANNABIS SATIVA 以下備考", [ONLINE], JPN5023009011, 17 April 2020 (2020-04-17), pages 1 - 12, ISSN: 0005753827 *
BRITISH JOURNAL OF PHARMACOLOGY, vol. 177, JPN6025017908, 16 July 2020 (2020-07-16), pages 4967 - 4970, ISSN: 0005753828 *
CYTOKINE AND GROWTH FACTOR REVIEWS, vol. 53, JPN6025024396, 20 May 2020 (2020-05-20), pages 63 - 65, ISSN: 0005753829 *
FATMA ELRASHDY ET AL.: ""On the potentialrole of exosomes in the COVID-19 reinfection/reactivation opportunity"", JOURNAL OF BIOMOLECULAR STRUCTURE AND DYNAMICS, vol. 39, no. 15, JPN6025050813, 9 July 2020 (2020-07-09), pages 5831 - 5842, ISSN: 0005753822 *
FLAVIA GIANNESSI ET AL.: ""The Role of Extracellular Vesicles as Allies of HIV, HCV and SARS Viruses"", VIRUSES, vol. 12, no. 5, JPN6025050814, 22 May 2020 (2020-05-22), pages 571, ISSN: 0005753823 *
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 11, JPN6025024397, 27 May 2020 (2020-05-27), pages 3809, ISSN: 0005753826 *
LIA COSTA ET AL.: ""Cannabinoid-inducedautophagy: Protective or death role?"", PROSTAGLANDINS AMD OTHER LIPID MEDIATORS, vol. 122, JPN6025050812, January 2016 (2016-01-01), pages 54 - 63, ISSN: 0005753821 *
NILS C. GASSEN ET AL.: ""Analysis ofSARS-CoV-2-controlled autophagy reveals spermidine, MK-2206, and niclosamide asputative", [ONLINE], JPN6025050815, 15 April 2020 (2020-04-15), ISSN: 0005753820 *
ON THE INHIBITION OF COVID-19 PROTEASE BY INDIAN HERBAL PLANTS: AN IN SILICO INVESTIGATION, ARXIV.ORG, E-PRINT ARCHIVE, QUANTITATIVE BIOLOGY, JPN6025024393, 5 April 2020 (2020-04-05), pages 1 - 14, ISSN: 0005753824 *
SIDDAPPA N BYRAREDDY; ET AL: "SARS-COV2 INDUCED RESPIRATORY DISTRESS: CAN CANNABINOIDS BE ADDED TO ANTI-VIRAL THERAPIES 以下備考", BRAIN, BEHAVIOR, AND IMMUNITY, vol. 87, JPN5023009010, 28 April 2020 (2020-04-28), US, pages 120 - 121, ISSN: 0005753830 *
STEPHEN W MAMBER; ET AL: "COULD UNCONVENTIONAL IMMUNOMODULATORY AGENTS HELP ALLEVIATE COVID-19 SYMPTOMS AND SEVERITY?", [ONLINE], JPN5023009012, April 2020 (2020-04-01), pages 1 - 15, ISSN: 0005753831 *

Also Published As

Publication number Publication date
CN120789031A (zh) 2025-10-17
EP4186496A4 (en) 2024-08-07
EP4186496A1 (en) 2023-05-31
CN111686095A (zh) 2020-09-22
US20230263811A1 (en) 2023-08-24
WO2022017304A1 (zh) 2022-01-27
EP4186496B1 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
JP7847940B2 (ja) ＳＡＲＳ－ＣｏＶ－２感染の治療における置換アミノプロピオン酸化合物の使用
JP2023535204A (ja) コロナウイルス感染症の治療におけるカンナビジオールの応用
CN111557939B (zh) 法匹拉韦在制备用于治疗冠状病毒感染的药物中的应用
JP2023534752A (ja) コロナウイルス感染症の治療におけるアルテミシニン化合物の応用
CN111743899B (zh) 硝唑尼特及其活性形式替唑尼特在制备用于治疗SARS-CoV-2感染的药物中的应用
JP2023512628A (ja) ＳＡＲＳ－ＣｏＶ－２感染症の治療における安息香酸塩化合物の利用
TWI800875B (zh) 苯芴醇及其衍生物在治療冠狀病毒感染方面的應用
CN111658648A (zh) 4-氨基喹啉类化合物在治疗冠状病毒感染方面的应用
HK40085142A (en) Application of cannabidiol in treatment of coronavirus infections
HK40085142B (en) Application of cannabidiol in treatment of coronavirus infections
JP2023512106A (ja) ＳＡＲＳ－ＣｏＶ－２感染の治療におけるリトナビルの適用
EA046990B1 (ru) Применение замещенных аминопропионатных соединений в лечении инфекции sars-cov-2
HK40029985A (en) Application of favipiravir in manufacture of a medicament for treating coronavirus infection
HK40029985B (en) Application of favipiravir in manufacture of a medicament for treating coronavirus infection
HK40033228B (en) Application of nitazoxanide and its active form tizoxanide in manufacture of a medicament for treating sars-cov-2 infection
HK40033228A (en) Application of nitazoxanide and its active form tizoxanide in manufacture of a medicament for treating sars-cov-2 infection
HK40031254A (en) Use of substituted aminopropionate compounds in manufacture of a medicament for the treatment of sars-cov-2 infection
HK40031254B (en) Use of substituted aminopropionate compounds in manufacture of a medicament for the treatment of sars-cov-2 infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240718

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260401